Dianthus Therapeutics, Inc. (DNTH)
NASDAQ: DNTH · Real-Time Price · USD
83.67
-3.49 (-4.00%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Dianthus Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 2.04 | 6.24 | 2.83 | 6.42 | 1.48 |
| Revenue Growth (YoY) | -67.35% | 120.63% | -55.96% | 334.76% | - |
| Gross Profit | 2.04 | 6.24 | 2.83 | 6.42 | 1.48 |
| Selling, General & Admin | 34.33 | 24.99 | 18.16 | 6.74 | 1.96 |
| Research & Development | 145.64 | 83.11 | 32.84 | 29.38 | 12.61 |
| Operating Expenses | 179.97 | 108.1 | 51 | 36.12 | 14.56 |
| Operating Income | -177.93 | -101.86 | -48.17 | -29.71 | -13.09 |
| Interest & Investment Income | 9.96 | 11.35 | 4.76 | 1.15 | 0 |
| Currency Exchange Gain (Loss) | -0.06 | -0.06 | -0.09 | 0.14 | -0.03 |
| Other Non Operating Income (Expenses) | -0.97 | -0.55 | -0.06 | -0.05 | - |
| EBT Excluding Unusual Items | -169.01 | -91.14 | -43.56 | -28.48 | -13.11 |
| Gain (Loss) on Sale of Investments | 6.67 | 6.17 | - | - | - |
| Pretax Income | -162.34 | -84.97 | -43.56 | -28.48 | -13.11 |
| Net Income | -162.34 | -84.97 | -43.56 | -28.48 | -13.11 |
| Net Income to Common | -162.34 | -84.97 | -43.56 | -28.48 | -13.11 |
| Shares Outstanding (Basic) | 39 | 33 | 5 | 1 | 4 |
| Shares Outstanding (Diluted) | 39 | 33 | 5 | 1 | 4 |
| Shares Change (YoY) | 15.92% | 546.44% | 489.48% | -78.17% | - |
| EPS (Basic) | -4.20 | -2.55 | -8.45 | -32.57 | -3.27 |
| EPS (Diluted) | -4.20 | -2.55 | -8.45 | -32.57 | -3.27 |
| Free Cash Flow | -129.27 | -78.29 | -36.97 | -29.21 | -9.94 |
| Free Cash Flow Per Share | -3.35 | -2.35 | -7.17 | -33.41 | -2.48 |
| Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Margin | -8739.34% | -1633.75% | -1704.67% | -462.91% | -886.59% |
| Profit Margin | -7973.33% | -1362.78% | -1541.22% | -443.76% | -888.14% |
| Free Cash Flow Margin | -6349.36% | -1255.57% | -1308.24% | -455.18% | -673.24% |
| EBITDA | -177.82 | -101.77 | -48.11 | -29.68 | - |
| D&A For EBITDA | 0.11 | 0.1 | 0.07 | 0.03 | - |
| EBIT | -177.93 | -101.86 | -48.17 | -29.71 | -13.09 |
| Revenue as Reported | 2.04 | 6.24 | 2.83 | - | - |
Source: S&P Capital IQ. Standard template.
Financial Sources.